Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide plus interleukin-2 in refractory acute leukemia (TRIAC)
2009-009938-33Phase 3Terminated
- Sponsor
- European Institute of Oncology
- Start
- Apr 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of temozolomide in Acute Leukaemia, sponsored by European Institute of Oncology. Primary endpoints: Overall survival and Progression-free survival. Started Apr 2009; status: terminated.
02
Drugs
temozolomide
03
Conditions
Acute Leukaemia
Beyond the preview
Go deeper on 2009-009938-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009938-33.